Emerging Topics in Precision Medicine: Non-Invasive Innovations Shaping Cancer and Immunotherapy Progress
Source abstract
Abstract
Cancer is a heterogeneous disease, resulting from genetic, epigenetic, signaling, and metabolic alterations, which are supported by a highly organized tumor microenvironment (TME) [...]
Only a short abstract or summary was supplied by the source.
Source: crossref · Quality: short
Research context
OpenAlex topics: Cancer Research and Treatments · Cancer Immunotherapy and Biomarkers · Cancer Cells and Metastasis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry, University of Nebraska, Lincoln, NE 68503, USA
Cancer Digital Twins, San Mateo, CA 94001, USA
References (24)
Show source-provided references
1. Emerging hallmarks and the rise of complexities and heterogeneity of tumor
2. Biray Avci, C., Goker Bagca, B., Nikanfar, M., Takanlou, L.S., Takanlou, M.S., and Nourazarian, A. (2024). Tumor microenvironment and cancer metastasis: Molecular mechanisms and therapeutic implications. Front. Pharmacol., 15.10.3389/fphar.2024.1442888 ↗
3. An overview of multiomics: A powerful tool applied in cancer molecular subtyping for cancer therapy10.1002/msp2.16 ↗
4. The challenge of early detection in cancer10.1126/science.aaz2078 ↗
5. Neagu, A.-N., Bruno, P.S., Josan, C.-L., Waterman, N., Morrissiey, H., Njoku, V.T., and Darie, C.C. (2025). In search of ideal solutions for cancer diagnosis: From conventional methods to protein biomarkers in liquid biopsy. Proteomes, 13.10.3390/proteomes13040047 ↗
6. Qiao, D., Wang, R.C., and Wang, Z. (2025). Precision oncology: Current landscape, emerging trends, challenges, and future perspectives. Cells, 14.10.20944/preprints202510.1139.v1 ↗
7. Artificial-intelligence-driven Innovations in Mechanistic Computational Modeling and Digital Twins for Biomedical Applications10.1016/j.jmb.2025.169181 ↗
8. Aghamiri, S.S., and Amin, R. (2025). Digital Twin-Based Multiscale Models for Biomarker Discovery in Kinase and Phosphatase Tumorigenic Processes. Kinases Phosphatases, 3.10.3390/kinasesphosphatases3030018 ↗
9. Diagnostic, predictive, prognostic, and therapeutic molecular biomarkers in third millennium: A breakthrough in gastric cancer10.1155/2017/7869802 ↗
10. Advances in engineering immune-tumor microenvironments on-a-chip: Integrative microfluidic platforms for immunotherapy and drug discovery10.1186/s12943-025-02479-4 ↗
11. Roma-Rodrigues, C., Mendes, R., Baptista, P.V., and Fernandes, A.R. (2019). Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci., 20.10.3390/ijms20040840 ↗
12. Current advances in comprehensive omics data mining for oncology and cancer research10.1016/j.bbcan.2023.189030 ↗
13. Multimodal data fusion for cancer biomarker discovery with deep learning10.1038/s42256-023-00633-5 ↗
14. 2D versus 3D tumor-on-chip models to study the impact of tumor organization on metabolic patterns in vitro10.1038/s41598-025-03504-8 ↗
15. Scaffold-based 3D cell culture models in cancer research10.1186/s12929-024-00994-y ↗
16. Real-world radiology data for artificial intelligence-driven cancer support systems and biomarker development10.1016/j.esmorw.2025.100120 ↗
17. Radiomics: The bridge between medical imaging and personalized medicine10.1038/nrclinonc.2017.141 ↗
18. Radiogenomics: Bridging the gap between imaging and genomics for precision oncology10.1002/mco2.722 ↗
19. Predicting treatment response from longitudinal images using multi-task deep learning10.1038/s41467-021-22188-y ↗
20. Alwahaibi, N., and Alwahaibi, M. (2025). Liver biopsy in the modern era: From traditional techniques to artificial intelligence and multi-omics integration. Front. Med., 12.10.3389/fmed.2025.1678753 ↗
21. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM)10.1016/j.annonc.2022.08.089 ↗
22. When tissue is an issue the liquid biopsy is nonissue: A review10.1007/s40487-021-00144-6 ↗
23. Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review10.1016/j.jlb.2024.100150 ↗
24. Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy10.1016/j.tranon.2025.102445 ↗